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Introduction {#sec1}
============

The genome-wide association study (GWAS) is one of the most commonly used pharmacogenomic approaches and provides positive statistical associations between variants and an investigated phenotype ([@bib19]). The vast majority of GWASs depend solely on genotyping chips that capture only hundreds of thousands of SNPs known as "tag SNPs" that are distributed across the entire genome ([@bib17]). Tag SNPs are SNPs in perfect linkage disequilibrium (LD) with many other neighboring SNPs and act as surrogates for their detection. Thus, a statistically significant GWAS hit is always co-inherited (linked) with several other SNPs that have indistinguishable statistical associations with the studied phenotype, leaving us with numerous possibilities to investigate in relation to causality. Owing to this LD issue, GWASs require downstream fine-mapping and further genetic examination at candidate loci to provide more comprehensive information about positive hits and eventually narrow down the list of potential causal SNPs for downstream mechanistic validation ([@bib18]).

Importantly, traditional fine-mapping essentially starts with identifying all variants that are co-inherited with a GWAS statistically significant association through increasing the genotyping density at candidate loci, for which imputation is the current standard approach. Imputation infers information about un-typed markers by comparing a genotyped cohort with a population-specific reference panel of haplotypes. HapMap3 ([@bib2]) and 1,000 genomes phase 3 ([@bib7], [@bib1]) reference panels are frequently used in imputation comprising 1.6 M and \~80 M genotyped SNPs in 1,184 and 2,504 individuals across different ancestor populations, respectively. Although imputation algorithms have added more power to GWASs, imputed genotypes accuracy is influenced by several factors. Although pre-phasing of the target dataset increases imputation speed, it decreases imputation accuracy as compared with no pre-phasing ([@bib23]). Imputation at chromosome X (apart from pseudo autosomal regions) for which males are haploid requires special care, as this hemizygosity reduces effective population size (N~e~), resulting in misleading longer shared haplotype stretches between individuals, and thus affects imputation accuracy ([@bib12]). Imputation accuracy is also inversely correlated with lower minor allele frequency making it more challenging to predict rare alleles ([@bib21]). Selecting the correct reference panel is very critical for imputation accuracy; thus, mixed ethnicities heterogeneous cohorts could affect predicted genotypes ([@bib3]). Different genotyping chips, study sample size, number of missed genotypes, and different imputation software could affect the accuracy of imputed genotypes ([@bib21]). Finally, imputation could provide information for previously identified SNPs in a particular population; however, it is unable to identify novel variant that might be harbored by a study cohort.

Recently, Oxford Nanopore Technologies has introduced a single molecule-based portable sequencer, MinION. MinION is capable of generating ultra-long sequence reads (up to 200 kb) that improves alignment and assembly. Nanopore sequencing utilizes synthetic nanopore proteins that are embedded into an electrically resistant polymer membrane. Ionic current is generated by applying voltage across the membrane at the beginning of the experiment, and base calling is generated by recording the disruption in ionic current caused by each nucleotide passing through nanopore protein ([@bib11]). MinION-derived long sequence reads have been successfully utilized to genotype single nucleotide variants (SNVs) and identify insertions, deletions, and translocations in different types of diseases ([@bib14], [@bib22], [@bib6]). The long sequencing reads generated by nanopore technology provide cost-effective, high depth of coverage and phasing of identified variants. Moreover, real-time data analysis provides the privilege of controlling the utilization of the MinION flow cell, as the sequencing could be stopped once sufficient coverage is reached.

Another unique advantage of Nanopore long reads is the feasibility of variants phasing. Phasing by definition is the assignment of variant alleles to paternal or maternal chromosomes and thus adds more useful information from each Nanopore sequencing experiment. Phasing could help identify inheritance patterns, allele-specific expression, haplotype resolution, and disease risk haplotypes, and accordingly, it may compensate for the analysis of relatives in rare clinical research samples ([@bib20]). The success rate of short sequence reads-based phasing is \~20% because reliable phasing requires that heterozygous variants are covered by the same sequence read, which is a big limitation for short sequence reads ([@bib8]). On contrary, Nanopore long reads facilitate phasing of genetic variants that are multiple kilobases apart directly from sequencing reads ([@bib15]), as well as complex genomic regions such as the major histocompatibility complex (MHC) locus that encompasses 4 Mb ([@bib10]).

Here, we use data from a recent large multi-center pediatric GWAS that revealed a candidate cardioprotective SNP (rs7853758, G\>A, L461L) in *SLC28A3,* previously called human concentrative nucleoside transporter-3 (hCNT3), as significantly associated with lower risk to develop doxorubicin-induced cardiotoxicity (DIC) ([@bib25]). This GWAS hit, rs7853758, is a synonymous SNP and thus most likely is not the causal SNP. In this work we sought to introduce a Nanopore-based precise and cost-effective pipeline for multiplexed targeted resequencing that provides high-level (\~500x) depth of coverage and helps identify potential causal SNP/haplotype.

Results and Discussion {#sec2}
======================

Nanopore Sequencing of *SLC28A3* and Long Sequence Reads Alignment {#sec2.1}
------------------------------------------------------------------

First, we PCR amplified and validated nine amplicons compassing *SLC28A3* gene ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B); we then sequenced the multiplexed amplicons from six patients using MinION Nanopore sequencer. Cumulative number of generated bases was 0.51, 1.1, 0.61, 0.87, 0.9, and 1.3 GB, and cumulative number of generated sequencing reads after demultiplexing was 103328, 182305, 117217, 195579, 226355, and 244678 reads, for DNA from patients BC01, BC02, BC03, BC04, BC05, and BC06, respectively ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Median read quality was 10, 10.2, 10.1, 10, 9.7, and 10.1 for BC01, BC02, BC03, BC04, BC05, and BC06, respectively ([Figure 1](#fig1){ref-type="fig"}A).Figure 1Nanopore Long Sequence Reads Encompassing *SLC28A3* Gene Locus(A) Pauvre plot showing reads mean Phred quality score, reads length, and number of reads.(B) Long-range PCR-based target enrichment for *SLC28A3* amplicons aligned to reference human genome (GRCh38) showing depth of coverage peaks at chr9: 84,274,029--84,349,802.(C) Zoom-in view at locus chr9: 84,274,029--84,349,802 encompassing *SLC28A3*.(D) Heatmap showing the correlation of the depth of coverage at *SLC28A3* locus between demultiplexed samples, BC01--BC06. The color code denotes value of Pearson correlation coefficient.

We next aligned sequence reads to reference human genome (GRCh38.p92) to check for non-specific PCR products. Aligning reads to reference genome resulted in a single peak encompassing *SLC28A3* gene locus in our six samples ([Figures 1](#fig1){ref-type="fig"}B and 1C). The median percent identity of aligned reads was 89%, 88.7%, 88.9%, 88.6%, 88.7%, and 88.8% for BC01, BC02, BC03, BC04, BC05, and BC06, respectively ([Figure S3](#mmc1){ref-type="supplementary-material"}). The depth of coverage at *SLC28A3* locus for all samples was well correlated, in that average Pearson correlation co-efficient of one sample in relation to the other five samples was 0.7, 0.9, 0.86, 0.86, 0.7, and 0.87 for BC01, BC02, BC03, BC04, BC05, and BC06, respectively ([Figure 1](#fig1){ref-type="fig"}D). Taken together, homogeneous depth of coverage and read quality of all multiplexed samples along with the availability of a 96-barcoding kit maximizes the utility of this pipeline.

Variant Identification from Aligned Nanopore Long Sequence Reads {#sec2.2}
----------------------------------------------------------------

We next sought to identify SNPs in the study patients using Nanopolish ([@bib16]) variant caller. In total 133 SNPs were identified, all of which have at least one variant allele in at least one patient ([Figure 2](#fig2){ref-type="fig"}A). The vast majority of identified SNPs are intronic (*n* = 93), 25 SNPs are located in 5′-UTR, 12 SNPs are located in 3′-UTR, in addition to three coding SNPs including two synonymous and one non-synonymous SNP ([Figure 2](#fig2){ref-type="fig"}A and [Table S6](#mmc1){ref-type="supplementary-material"}). Of 133 identified SNPs, 28 are novel SNPs that have not been previously reported ([Table S6](#mmc2){ref-type="supplementary-material"}). For all patients, Nanopore genotypes of the original GWAS hit, rs7853758, were in concordance with the GWAS-chip genotypes ([Figure 2](#fig2){ref-type="fig"}B). Novel SNPs included 14 intronic SNPs, 12 SNPs located in 5′-UTR, one SNP located in 3′-UTR, in addition to one non-synonymous SNP located at chr9:84285427 results in amino acid alteration Ala522Val ([Table S6](#mmc2){ref-type="supplementary-material"}). The identified novel SNPs are co-inherited in both cardiotoxicity and cardioprotective patients and thus unlikely to be involved in doxorubicin-induced cardiotoxicity. However, identification of SNPs that are not captured by the GWAS SNP-chip is a major strength of the proposed pipeline, as these SNPs might have been missed if imputation only was implemented for fine-mapping.Figure 2Variants Calling after *SLC28A3* Nanopore Sequencing(A) Consequence and location of identified SNPs (*n* = 133).(B) Aligned sequence reads at the location of the original GWAS hit (rs7853758, G\>A, L461L) confirm that BC01, BC02, and BC06 harbor homozygous reference genotype (GG), whereas BC03, BC04, and BC05 harbor heterozygotes variant genotype (GA).(C) Effect of depth of coverage on variant calling after Nanopore sequencing of study samples (*n* = 6). Sequence reads were down-sampled down to 10% of the cumulative read counts.(D) Genotypes (*n* = 563) concordance between nanopore sequencing and SNP-chip technologies. The genotypes are homozygous reference (REF), heterozygous (ALT1), and homozygous non-reference (ALT2). Genotype pairs such as REF/REF represent genotype calls by nanopore and by the Omni chip, respectively. REF/REF, ALT1/ALT1, and ALT2/ALT2 indicate concordant genotypes. Line graph represents genotype percentage of total.

Effect of Depth of Coverage on Genotype Concordance Rate {#sec2.3}
--------------------------------------------------------

To investigate how low coverage depth might affect variant calling from Nanopore reads, each bam file containing all sequence reads from a particular patient was down-sampled to include only 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, and 10% of the accumulative reads. Then variants called from down-sampled bam files were compared with variants called from the main bam file that contains all accumulative reads. Lower depth of coverage did not show dramatic effect on Nanopore-based variant calling. The mean genotypes concordance rate across all six samples was 98.73%, 97.98%, 97.44%, 97.77%, 96.86%, 96.70%, 96.18%, 96.35%, and 93.19% with decreasing coverage depth from 100% down to 10% ([Figure 2](#fig2){ref-type="fig"}C). This finding shows that \~500x depth of coverage is sufficient for reliable variant calling from Nanopore sequence reads. Moreover, the cumulative yield of a single Nanopore flow cell ranges between 7 and 10 Gb, and thus, when coupled with the available barcoding kits, this pipeline could be used to examine several candidate loci in at least 96 multiplexed samples.

Genotype Concordance between Nanopore SNPs and InfiniumOmniExpress-24v1-2 {#sec2.4}
-------------------------------------------------------------------------

We had access to chip-based 94 genotyped loci distributed across *SLC28A3* gene in the six patients we sequenced (*n* = 563, one genotype was missed in one sample), allowing us to check for concordance rate at these overlapping sites. Using SnpSift ([@bib4]), we examined genotype concordance between the nanopore sequencing and InfiniumOmniExpress-24v1-2 genotyping chip. We found that 514 of the 563 overlapping genotypes were concordant (91.3%), i.e., both technologies called the same genotype (homozygous reference, heterozygous, or homozygous non-reference) at the same loci for a particular patient ([Figure 2](#fig2){ref-type="fig"}D and [Table S7](#mmc1){ref-type="supplementary-material"}).

Functional Annotation Analysis Identifies Potential Causal SNP/Haplotype {#sec2.5}
------------------------------------------------------------------------

We next examined which SNPs are linked in cardioprotected patients. Of the 133 identified SNPs, 24 SNPs including the GWAS hit are co-inherited in cardioprotected patients ([Figure 3](#fig3){ref-type="fig"}A and [Table S6](#mmc2){ref-type="supplementary-material"}). These 23 SNPs are distributed as follows: eight SNPs are located in 3′ UTR, 14 SNPs are intronic, and 1 coding synonymous SNP ([Figure 3](#fig3){ref-type="fig"}B). Interestingly, seven SNPs are located within a long non-coding RNA, *AL356134.1*, that overlaps with *SLC28A3*. Moreover, SNP rs11140490 is located at the splice site of the first exon of *AL356134.1* ([Figure 3](#fig3){ref-type="fig"}C).Figure 3Identification of Potential Causal SNP after Nanopore Sequencing(A) Heatmap showing identified SNP (*n* = 133) genotypes in all study patients (*n* = 6) after *SLC28A3* sequencing. A total of 133 SNPs have been identified, all of which have at least one variant allele in at least one of the study samples. SNPs (*n* = 24) marked on the heatmap by black rectangle are those that are coinherited in Non-TOX (no toxicity) samples but not in TOX (toxicity).(B) The distribution of potential *SLC28A3* haplotype (24 SNPs) across *SLC28A3* and the overlapping long noncoding RNA, *AL356134.1*.(C) Zoom-in view of SNP rs11140490 located in the splice site of the first exon of *AL356134.1*.(D) Regulatory effect of candidate SNPs on chromatin feature binding sites.(E--G) SNPs functional annotation using chromatin regulatory analysis for SNP rs11140490 (E), rs4877835 (F), and rs7853758 (G). Log2 fold change measures the fold change in the probability of observing a binding site for relevant chromatin feature between reference and alternative allele for a particular SNP ([@bib26]). Significant (E-value ≤0.02) predicted effect of a SNP on a particular chromatin feature binding site is denoted by blue dots.(H) Conservation analysis of *SLC28A3* candidate SNPs using PhastCons database and SnpSift ([@bib4]).(I) eQTL annotation for candidate SNPs using Genotype-Tissue Expression (GTEx) project database.(J) Overall prioritization of candidate causal SNPs based on functional annotation analyses including eQTL annotation, chromatin regulatory analyses, and overlapping with regulatory regions in cardiac tissues.

In order to narrow down the list of potential variants implicated in the cardioprotective phenotype after doxorubicin treatment, we investigated the regulatory properties of all non-coding candidate SNPs. Using ENCODE and Roadmap Epigenomics ([@bib13]) data and DeepSEA ([@bib26]) algorithm, we examined the functional effect of each SNP on altering chromatin features (transcription factors, DNase hypersensitive site, and histone marks) binding sites. Among all SNPs, rs11140490 and rs4877835 have the most substantial regulatory effects as both SNPs have been predicted to be involved in altering the binding site of 206 and 204 chromatin features, respectively ([Figures 3](#fig3){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}, [Tables S8](#mmc1){ref-type="supplementary-material"} and [S9](#mmc1){ref-type="supplementary-material"}). In that, SNP rs11140490 is predicted to alter the binding sites of 43 features with log2 fold change of ≥ 1 ([Figure 3](#fig3){ref-type="fig"}E), whereas rs4877835 is predicted to alter the binding sites of only four features with log2 fold change of ≥ 1 ([Figure 3](#fig3){ref-type="fig"}F). Importantly, the primary GWAS significant association does not show any chromatin regulatory effect ([Figure 3](#fig3){ref-type="fig"}G).

Since doxorubicin-induced cardiotoxicity affects mainly heart cells, we then performed an additional regulatory analysis exclusively focusing on human cardiac tissue, and for that we used ensemble regulatory build that includes transcription factors, histone mark, and DNase hypersensitive regions. Six SNPs, rs11140490, rs4877835, rs4877831, rs7047898, rs885004, and rs10868137, are found to be located in at least one regulatory region in human cardiac tissue ([Table S10](#mmc1){ref-type="supplementary-material"} and [Figure S5](#mmc1){ref-type="supplementary-material"}).

Then using phastCons database and SnpSift ([@bib4]), we checked which of candidate SNPs are located in a highly conserved locus. We found that SNP rs4877835 is located in a highly conserved locus as compared with rs11140490, and rs10868137 with a conservation score of 0.75, 0.04, and 0.001, respectively ([Figure 3](#fig3){ref-type="fig"}H).

Finally, to investigate further regulatory consequences of these candidate SNPs, we used the Genotype-Tissue Expression (GTEx) project database (<https://www.gtexportal.org/home/>) and investigated which of the identified candidate SNPs have been shown to be an expression quantitative trait loci (eQTL). Almost all of the candidate SNPs have been previously identified as eQTL in cultured fibroblasts, thyroid, and brain tissues. In that, SNP rs4877831 is the most significant eQTL in cultured fibroblasts and SNP rs7030019 is the most significant eQTL in both thyroid and brain tissues ([Figure 3](#fig3){ref-type="fig"}I and [Table S11](#mmc1){ref-type="supplementary-material"}).

These findings when taken together suggest that rs11140490 is the SNP with the highest likelihood to be causal. However, other candidate SNPs with positive functional annotations might also have a protective role against DIC ([Figure 3](#fig3){ref-type="fig"}J). SNP rs11140490 alone or in interaction with other identified candidate SNPs revealed from this analysis ([Figure 3](#fig3){ref-type="fig"}J) could affect the transcription and/or expression of *AL356134.1*, which regulates the expression of doxorubicin-related genes including *SLC28A3* and eventually regulates patients\' susceptibility to doxorubicin-induced cardiotoxicity.

Fine-Mapping at *SLC28A3* Locus Using Genotype Imputation {#sec2.6}
---------------------------------------------------------

We next sought to compare Nanopore-based fine mapping and imputation-based fine mapping at the *SLC28A3* locus. The original GWAS that identified SNP rs7853758 used a genotyping chip that covers \~2,000 SNPs across 220 ADME (absorption, distribution, metabolism, and excretion)-related genes, which included 23 SNPs distributed across SLC28A3 ([@bib25]). Genotype imputation of additional SNPs not present on the GWAS genotyping platform was done using SHAPEIT ([@bib5]) for phasing followed by IMPUTE2 ([@bib9]) with 1K genomes reference panel. To validate the imputation analysis, known GWAS genotypes were masked one variant at a time and imputed using the remaining study and reference data. Internal cross-validation showed that the mean concordance between imputed genotypes (including the original GWAS hit, rs7853758) and the original genotypes was 98.5% ([Table S12](#mmc1){ref-type="supplementary-material"}).

In total, 817 additional SNPs were imputed with an accuracy ranging from 0%--100%. In that, 73 SNPs were imputed with at least 90% accuracy and 52 SNPs were imputed with at least 99% accuracy ([Figure 4](#fig4){ref-type="fig"}A). Schurz et al. among others showed that imputation accuracy significantly decreases with lower minor allele frequency (MAF) SNP ([@bib24]). Similarly, we have noticed that imputation accuracy is inversely correlated with SNPs MAF, emphasizing the value of the Nanopore-based pipeline in identifying rare variants that could have been otherwise missed ([Figure 4](#fig4){ref-type="fig"}B). We then focused on the Nanopore-identified cardioprotective haplotype (24 SNPs) that is co-inherited in cardioprotected patients. Only 19 SNPs within this haplotype were imputed in the study cohort ([Figure 4](#fig4){ref-type="fig"}C), whereas five SNPs that have been identified with the Nanopore pipeline were not imputed. Although the European population represented by this study cohort has substantial long LD haplotype stretches, imputation was not able to identify all SNPs identified by Nanopore sequencing at the investigated candidate locus. Thus, we believe that Nanopore sequencing pipeline provides a comprehensive fine-mapping approach specially when studying populations with higher recombination rates and shorter haplotype stretches such as the African population. Similarly, Nanopore pipeline is very useful when studying cohorts with no available reference panel. When analyzing such cohorts and in case of any limitation that prohibits sequencing all the cohort samples, a subset of samples might be sequenced at interesting loci using the Nanopore pipeline, and the generated data could serve as a reference panel for this particular cohort and is subsequently used for imputation-based fine-mapping for the rest of the cohort samples.Figure 4Genetic Analysis at *SLC28A3* Candidate Locus in Control Individuals(A and B) (A) Genotype imputation of additional SNPs not present on the original GWAS genotyping platform. Genotype imputation was done using SHAPEIT for phasing followed by IMPUTE2 ([@bib9]) with 1K genomes reference panel. (B) Imputation accuracy is inversely correlated with MAF.(C) Comparison between Nanopore pipeline-identified candidate SNPs (*n* = 24) and imputation-based identified SNPs (*n* = 19) at *SLC28A3* locus.(D--F) Haplotype structure of *SLC28A3* locus in control individuals (*n* = 99). (D) Pairwise linkage disequilibrium (D′) for all SNPs spread over \~100 kb encompassing *SLC28A3* locus. The linkage disequilibrium (D′) is indicated in the small boxes colored red or blue (a color legend is provided). LOD, log of the likelihood odds ratio. (E) LD haplotype structure for Nanopore-identified haplotype that is spread over 32 kb and comprises 24 SNPs that are co-inherited only in cardioprotected patients. The reference SNP numbers (rs) are indicated on top. Haplotype Block 1 (outlined by black triangle) is spread over 8 kb and is composed of seven SNPs that are located within a long non-coding RNA (LNCRNA*), AL356134.1*, that overlaps with *SLC28A3*. (F) The cardioprotective haplotype allelic frequencies in control individuals. Each SNP is labeled as follow: rs id (SNP number on the LD block in \[B\], reference allele \> variant allele). SNP rs7853758 (in bold) is the primary GWAS hit. For each SNP, variant alleles are in red. Haplotype II that includes the variant alleles for all the seven SNPs have an allelic frequency of 17.7% in the CEU population. VCF file containing genotype calls for 99 CEU individuals was downloaded from the 1,000 genomes database for the 9p21.3 locus (chr9:84274029--84349802). Using VCFtools, VCF was converted to PED and MAP files. Plink ([@bib27]) was used to calculate linkage disequilibrium between SNPs, and finally the haplotype LD map was generated using Haploview V4.2.

Haplotype Structure of *SLC28A3* Locus in Control Individuals (*n* = 99) {#sec2.7}
------------------------------------------------------------------------

In order to confirm the linkage disequilibrium pattern of the Nanopore-identified cardioprotective haplotype (24 SNPs), we investigated the structure of this haplotype in 99 whole-genome sequenced control individuals from the CEU (Utah Residents \[CEPH\] with Northern and Western European Ancestry) population. The 24 SNPs constituting this cardioprotective haplotype are in high LD with an average D′ and R^2^ of 0.99 and 0.84, respectively ([Figures 4](#fig4){ref-type="fig"}D and 4E, and [Table S13](#mmc3){ref-type="supplementary-material"}). Seven SNPs of the main haplotype are located within a long non-coding RNA (LNCRNA), *AL356134.1*, that overlaps with S*LC28A3,* forming a sub-haplotype block ([Figure 4](#fig4){ref-type="fig"}E). The seven SNPs that constitute this sub-haplotype are rs11140490 (A\>G), rs10868135 (T\>C), rs4877831 (C\>G), rs4877833 (T\>C), rs7853066 (A\>G), rs7853758 (G\>A), and rs7030019 (A\>G).

We next investigated the allelic frequency of the *AL356134.1* overlapping sub-haplotype. Seven structural Haplotype I-VII were identified ([Figure 4](#fig4){ref-type="fig"}F), in that Haplotype I comprises the reference alleles for all seven SNPs (ATCTAGA) and is inherited in 71.7% of the examined population, whereas haplotype II is built of the variants alleles for all seven SNPs (GCGCGAG) and is inherited in 17.7% of the examined population ([Figure 4](#fig4){ref-type="fig"}F). This finding is consistent with the linkage disequilibrium pattern identified by the Nanopore pipeline.

Nanopore Pipeline Is a Cost-Effective Pipeline for Candidate Loci Sequencing {#sec2.8}
----------------------------------------------------------------------------

A standard single MinION flow cell run (48 h) generates 4--8 Gb of useful sequencing data, and herein we were able to generate \~6 Gb from one flow cell. Although the newer generation of MinION flow cells are able to generate up to 30 Gb of sequencing data in a single run (<https://nanoporetech.com/products/comparison>), the cost estimates calculated here are based on an output of 5 Gb per flow cell. The generated 5 Gb are equivalent to 10 Mb with a depth of coverage of 500x that is suitable for downstream variant calling. The availability of Nanopore barcoding kits enables the multiplexing of up to 96 samples. One MinION flow cell generates 10 Mb (500x coverage) and thus is enough to sequence \~104 kb (500x coverage) in 96 samples that costs as low as \$8/sample. This cost includes the cost of the MinION sequencer, MinION flow cell, library preparation, and samples barcoding. Nanopore sequencing for candidate loci is thus significantly more cost-effective as compared to other sequencing approaches including the commonly used Illumina targeted sequencing that costs \~\$50/sample. These cost estimates do not include the cost of the Miseq Illumina sequencer, which is about \$125,000. On contrary, the Nanopore MinION sequencer is included in a basic starter kit that also includes two flow cells and a sequencing kit all of which costs \$1,000. A detailed cost estimates for Nanopore sequencing and Illumina targeted sequencing are mentioned in [Table S14](#mmc1){ref-type="supplementary-material"}.

In summary, Nanopore long-read sequences coupled with long-range PCR comprises a useful aide for comprehensive post-GWAS fine-mapping and helps identification of causal SNP/haplotype. Using the herein introduced pipeline, 100 kb candidate loci sequencing with ample depth of coverage of 500x, that is compatible with reliable downstream variant calling would cost \~\$10/sample. Real-time analysis of Nanopore sequencing run makes other permutations such as examining bigger candidate loci and smaller number of samples also possible at similar cost. Nanopore-based fine-mapping is able to prioritize candidate causal SNPs and is more comprehensive as compared with imputation-based fine mapping. The Nanopore-based approach eliminates the need for costly traditional post-GWAS resequencing strategies while still providing extensive information for examined genetic loci. Fine-mapping approaches, weather it is statistics based or functional annotation based when coupled to our pipeline that provides high-density genotyping information, will substantially help prioritization and identification of causal SNPs. The constant improvement in long reads aligning and variant calling algorithms will definitely expand the utility of this pipeline in the future.

Limitation of the Study {#sec2.9}
-----------------------

In this work we provide a proof of principle for the application of Nanopore sequencing in post-GWAS fine-mapping and pinpointing of potential causal SNPs. However, low sample size is a limitation of our study. Herein, six well-phenotyped, doxorubicin-exposed patients from the Canadian cohort were specifically re-recruited according to the original inclusion criteria. Re-recruiting more patients with similar strict criteria is very challenging and time consuming. Our proposed pipeline is worth testing in a larger cohort.

Methods {#sec3}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

The data that support the findings of this study are available from the corresponding author upon reasonable request.
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